Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?

Bibliographic Details
Title: Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?
Authors: Sviatoslav Chekhun, Assumpció Lopez-Paradís, Aintzane Urbizu, Teresa Morán, Anabel Mañes, Marc Cucurull, Carlos Martínez-Barenys, Iris Teruel, Gloria Moragas, Enric Carcereny, Ana Maria Muñoz Mármol, Maria Saigí
Source: Exploration of Targeted Anti-tumor Therapy, Vol 4, Iss 6, Pp 1182-1187 (2023)
Publisher Information: Open Exploration Publishing Inc., 2023.
Publication Year: 2023
Collection: LCC:Internal medicine
Subject Terms: lung adenocarcinoma, epidermal growth factor receptor, oligoprogression, targeted therapy, epidermal growth factor receptor-tyrosine kinase inhibitors, Internal medicine, RC31-1245
More Details: Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown impressive results in EGFR mutant lung cancer (LC) patients in terms of disease control rate with a positive impact on overall survival. Nevertheless, after months of treatment with targeted therapy, progression inevitably occurs. Some patients develop oligoprogression and local treatment is required for optimal disease control while maintaining EGFR-TKIs. This work features a clinical case of a patient harboring an EGFR mutant LC undergoing oligoprogression to EGFR-TKIs, first into the brain and afterward to the primary tumor, requiring local ablative strategies, including primary tumor resection three years after the start of osimertinib. Currently, the patient is still alive and continues with a complete response upon EGFR-TKIs maintenance. Hence, oligoprogression, even in driven oncogenic tumors, represents a distinct biological entity and potential curative disease that deserves particular consideration in multidisciplinary tumor boards. In this case, tumor primary resection after three years of the initial diagnosis represents a paradigm shift in the treatment of EGFR mutant patients.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2692-3114
Relation: https://www.explorationpub.com/Journals/etat/Article/1002191; https://doaj.org/toc/2692-3114
DOI: 10.37349/etat.2023.00191
Access URL: https://doaj.org/article/548b16587d6e4b5780c5798654aef425
Accession Number: edsdoj.548b16587d6e4b5780c5798654aef425
Database: Directory of Open Access Journals
More Details
ISSN:26923114
DOI:10.37349/etat.2023.00191
Published in:Exploration of Targeted Anti-tumor Therapy
Language:English